AAAAAA

   
Results: 1-7 |
Results: 7
P450 interaction with HIV protease inhibitors: Relationship between metabolic stability, inhibitory potency, and p450 binding spectra
Authors: Chiba, M Jin, LX Neway, W Vacca, JP Tata, JR Chapman, K Lin, JH
Citation: M. Chiba et al., P450 interaction with HIV protease inhibitors: Relationship between metabolic stability, inhibitory potency, and p450 binding spectra, DRUG META D, 29(1), 2001, pp. 1-3
New advances in the discovery of thrombin and factor Xa inhibitors
Authors: Vacca, JP
Citation: Jp. Vacca, New advances in the discovery of thrombin and factor Xa inhibitors, CURR OP C B, 4(4), 2000, pp. 394-400
Bicyclic pyridones as potent, efficacious and orally bioavailable thrombininhibitors
Authors: Coburn, CA Rush, DM Williams, PD Homnick, C Lyle, EA Lewis, SD Lucas, BJ Di Muzio-Mower, JM Juliano, M Krueger, JA Vastag, K Chen, IW Vacca, JP
Citation: Ca. Coburn et al., Bicyclic pyridones as potent, efficacious and orally bioavailable thrombininhibitors, BIOORG MED, 10(10), 2000, pp. 1069-1072
4-aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells
Authors: Wai, JS Egbertson, MS Payne, LS Fisher, TE Embrey, MW Tran, LO Melamed, JY Langford, HM Guare, JP Zhuang, LG Grey, VE Vacca, JP Holloway, MK Naylor-Olsen, AM Hazuda, DJ Felock, PJ Wolfe, AL Stillmock, KA Schleif, WA Gabryelski, LJ Young, SD
Citation: Js. Wai et al., 4-aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells, J MED CHEM, 43(26), 2000, pp. 4923-4926
Identification of MK-944a: A second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors
Authors: Dorsey, BD McDonough, C McDaniel, SL Levin, RB Newton, CL Hoffman, JM Darke, PL Zugay-Murphy, JA Emini, EA Schleif, WA Olsen, DB Stahlhut, MW Rutkowski, CA Kuo, LC Lin, JH Chen, IW Michelson, SR Holloway, MK Huff, JR Vacca, JP
Citation: Bd. Dorsey et al., Identification of MK-944a: A second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors, J MED CHEM, 43(18), 2000, pp. 3386-3399
Antithrombotic efficacy of thrombin inhibitor L-374,087: Intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis
Authors: Cook, JJ Gardell, SJ Holahan, MA Sitko, GR Stump, GL Wallace, AA Gilberto, DB Hare, TR Krueger, JA Dyer, DL Sanderson, PEJ Vacca, JP Shafer, JA Lynch, JJ
Citation: Jj. Cook et al., Antithrombotic efficacy of thrombin inhibitor L-374,087: Intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis, J PHARM EXP, 289(1), 1999, pp. 503-510
Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase
Authors: Liverton, NJ Butcher, JW Claiborne, CF Claremon, DA Libby, BE Nguyen, KT Pitzenberger, SM Selnick, HG Smith, GR Tebben, A Vacca, JP Varga, SL Agarwal, L Dancheck, K Forsyth, AJ Fletcher, DS Frantz, B Hanlon, WA Harper, CF Hofsess, SJ Kostura, M Lin, J Luell, S O'Neill, EA Orevillo, CJ Pang, M Parsons, J Rolando, A Sahly, Y Visco, DM O'Keefe, SJ
Citation: Nj. Liverton et al., Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase, J MED CHEM, 42(12), 1999, pp. 2180-2190
Risultati: 1-7 |